Integrated Biology Platform
Delivering comprehensive solutions from early discovery through IND-enabling translational studies
Oncology
Comprehensive in vivo oncology platform for evaluating therapeutic efficacy, target dependency, and resistance mechanisms across mutation-driven, patient-derived, syngeneic, and orthotopic tumor systems.
Xenograft models
Ba/F3-derived xenograft models
- 150+ kinase-driven tumor models based on engineered Ba/F3 systems
- Coverage of clinically relevant mutations and resistance variants across 70+ kinases
- Evaluation of mutation-driven drug sensitivity and acquired resistance mechanisms
CDX — Cell Line-Derived Xenograft Models
- Extensive model library covering 24+ cancer indications
- 100+ validated CDX models across solid and hematological malignancies
- Diverse cell line panels representing clinically relevant genetic and molecular backgrounds
PDX — Patient-Derived Xenograft Models
- 480+ validated PDX models preserving tumor heterogeneity, architecture, and genetic background
- Clinically relevant efficacy evaluation maintaining patient-specific biology
- Biomarker-driven study design for precision oncology applications
Syngeneic models
- Tumors established in fully functional, immune-intact syngeneic mouse systems
- Ideal for evaluation of immune checkpoint inhibitors, immuno-oncology, and combination regimens
Orthotopic tumor models
- Tumor implantation at anatomically relevant sites (e.g., intracranial, orthotopic lung, liver)
- Recapitulation of native tumor microenvironment and vascularization
- Evaluation of tissue-specific drug distribution, penetration, and efficacy
Applications
- Efficacy evaluation of small molecules, biologics, and targeted therapies
- Target validation in genetically defined tumor models
- Resistance mechanism and mutation profiling
- Translational oncology and IND-enabling studies
Reprogramming Cells, Empowering Medicine
©2026 PRECEDO Biotechnology Co., Ltd. Powered by：www.300.cn